Esperion (ESPR) announced that it has entered into a settlement agreement with Dr. Reddy’s Laboratories (RDY) and its affiliate Dr. Reddy’s Laboratories. This agreement resolves the patent litigation brought by Esperion against Dr. Reddy’s Laboratories in response to Dr. Reddy’s Laboratories’ Abbreviated New Drug Application, ANDA, seeking approval to market a generic version of each of NEXLETOL and NEXLIZET prior to the expiration of the applicable patents. Pursuant to the agreement, Dr. Reddy’s Laboratories has agreed not to market a generic version of either NEXLETOL or NEXLIZET in the United States prior to April 19, 2040, unless certain limited circumstances customarily included in these types of agreements occur.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ESPR:
- Esperion management to meet with Cantor Fitzgerald
- Esperion price target raised to $9 from $7 at Cantor Fitzgerald
- Esperion’s US Market Stagnation Overshadows Japanese Approval, Justifying Sell Rating
- Esperion’s Strategic Milestone: Nexletol Approval in Japan Boosts Financial Outlook with $120 Million Potential
- Esperion’s Strategic Advancements: Regulatory Approval and Market Expansion Boost